Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.41 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.57 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29421834 | 1.00 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL957295 | 1.00 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| SCHEMBL127882 | 0.98 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| SCHEMBL29371176 | 0.98 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3416002 | 0.96 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Cysteamine SCHEMBL2637878 | 0.93 | EHMT2 (0.50) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10803237 | 0.89 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28391982 | 0.89 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10806037 | 0.88 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 | |
| SCHEMBL10802711 | 0.87 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GHRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334117-B1 | ANTIBACTERIAL AGENTS COMPRISING CONJUGATES OF GLYCOPEPTIDES AND PEPTIDIC MEMBRANE-ASSOCIATING ELEMENTS | CAMBRIDGE ENTPR LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-7078380-B2 | Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-07-18 | — | — | US | disclosed |
| US-20040242477-A1 | Protein modification reagents | ADPROTECH LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| US-20040106544-A1 | Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements | CAMBRIDGE ENTERPRISE LTD. (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1334117-A1 | ANTIBACTERIAL AGENTS COMPRISING CONJUGATES OF GLYCOPEPTIDES AND PEPTIDIC MEMBRANE-ASSOCIATING ELEMENTS | Cambridge University Technical Services Limited (GB) | 2003-08-13 | — | — | EP | disclosed |
| WO-2003006433-A1 | PROTEIN MODIFICATION REAGENTS | ADPROTECH LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002036612-A1 | ANTIBACTERIAL AGENTS COMPRISING CONJUGATES OF GLYCOPEPTIDES AND PEPTIDIC MEMBRANE-ASSOCIATING ELEMENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| US-5352798-A | Intermediates for mitomycins; antitumor agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-04 | — | — | US | disclosed |
| US-5103018-A | Antitumor agent; side effect reduction | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0280741-A1 | MITOMYCIN DERIVATIVES | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1988-09-07 | — | — | EP | disclosed |
| EP-0116208-B1 | MITOMYCIN ANALOGUES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1988-03-30 | — | — | EP | disclosed |
| EP-0116208-A1 | Mitomycin analogues | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106544-A1 | Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements | VMA21, VIP, MLX | HRH1 3053/4885HDAC1 2327/4885HDAC2 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.